» Articles » PMID: 15163728

Circulating Anti-wild-type Adeno-associated Virus Type 2 (AAV2) Antibodies Inhibit Recombinant AAV2 (rAAV2)-mediated, but Not RAAV5-mediated, Gene Transfer in the Brain

Overview
Journal J Virol
Date 2004 May 28
PMID 15163728
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Epidemiological studies report that 80% of the population maintains antibodies (Ab) to wild-type (wt) adeno-associated virus type 2 (AAV2), with 30% expressing neutralizing Ab (NAb). The blood-brain barrier (BBB) provides limited immune privilege to brain parenchyma, and the immune response to recombinant AAV (rAAV) administration in the brain of a naive animal is minimal. However, central nervous system transduction in preimmunized animals remains unstudied. Vector administration may disrupt the BBB sufficiently to promote an immune response in a previously immunized animal. We tested the hypothesis that intracerebral rAAV administration and readministration would not be affected by the presence of circulating Ab to wt AAV2. Rats peripherally immunized with live wt AAV2 and naive controls were tested with single intrastriatal injections of rAAV2 encoding human glial cell line-derived neurotrophic factor (GDNF) or green fluorescent protein (GFP). Striatal readministration of rAAV2-GDNF was also tested in preimmunized and naive rats. Finally, serotype specificity of the immunization against wt AAV2 was examined by single injections of rAAV5-GFP. Preimmunization resulted in high levels of circulating NAb and prevented transduction by rAAV2 as assessed by striatal GDNF levels. rAAV2-GFP striatal transduction was also prevented by immunization, while rAAV5-GFP-mediated transduction, as assessed by stereological cell counting, was unaffected. Additionally, inflammatory markers were present in those animals that received repeated administrations of rAAV2, including markers of a cell-mediated immune response and cytotoxic damage. A live virus immunization protocol generated the circulating anti-wt-AAV Ab seen in this experiment, while human titers are commonly acquired via natural infection. Regardless, the data show that the presence of high levels of NAb against wt AAV can reduce rAAV-mediated transduction in the brain and should be accounted for in future experiments utilizing this vector.

Citing Articles

Adeno-Associated Viral Vectors in the Treatment of Epilepsy.

Mullagulova A, Timechko E, Solovyeva V, Yakimov A, Ibrahim A, Dmitrenko D Int J Mol Sci. 2024; 25(22).

PMID: 39596149 PMC: 11593886. DOI: 10.3390/ijms252212081.


In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection.

Tkaczyk C, Newton M, Patnaik M, Thom G, Strain M, Gamson A Mol Ther. 2024; 32(8):2505-2518.

PMID: 38822525 PMC: 11405172. DOI: 10.1016/j.ymthe.2024.05.036.


MSC based gene delivery methods and strategies improve the therapeutic efficacy of neurological diseases.

Zhou H, He Y, Xiong W, Jing S, Duan X, Huang Z Bioact Mater. 2022; 23:409-437.

PMID: 36474656 PMC: 9713256. DOI: 10.1016/j.bioactmat.2022.11.007.


Rational engineering of adeno-associated virus capsid enhances human hepatocyte tropism and reduces immunogenicity.

Han J, Zhu L, Zhang J, Guo L, Sun X, Huang C Cell Prolif. 2022; 55(12):e13339.

PMID: 36135100 PMC: 9715358. DOI: 10.1111/cpr.13339.


A versatile toolkit for overcoming AAV immunity.

Li X, Wei X, Lin J, Ou L Front Immunol. 2022; 13:991832.

PMID: 36119036 PMC: 9479010. DOI: 10.3389/fimmu.2022.991832.


References
1.
Hernandez Y, Wang J, Kearns W, Loiler S, Poirier A, Flotte T . Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol. 1999; 73(10):8549-58. PMC: 112875. DOI: 10.1128/JVI.73.10.8549-8558.1999. View

2.
Zolotukhin S, Byrne B, Mason E, Zolotukhin I, Potter M, Chesnut K . Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999; 6(6):973-85. DOI: 10.1038/sj.gt.3300938. View

3.
Erles K, Sebokova P, Schlehofer J . Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999; 59(3):406-11. DOI: 10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-n. View

4.
Beck S, Jones L, Chesnut K, Walsh S, Reynolds T, Carter B . Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol. 1999; 73(11):9446-55. PMC: 112979. DOI: 10.1128/JVI.73.11.9446-9455.1999. View

5.
Corti O, Sanchez-Capelo A, Colin P, Hanoun N, Hamon M, Mallet J . Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc Natl Acad Sci U S A. 1999; 96(21):12120-5. PMC: 18422. DOI: 10.1073/pnas.96.21.12120. View